

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

https://marketpublishers.com/r/U456B6CD49CEN.html

Date: February 2017

Pages: 620

Price: US\$ 8,820.00 (Single User License)

ID: U456B6CD49CEN

Abstracts

Complete report \$9,800. DataPack (test volumes, sales forecasts, supplier shares) \$6,400. **Highlights**

Comprehensive 620-page analysis of the US tumor marker testing market.

Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Five-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.

Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.

Current instrumentation technologies and feature comparison of leading analyzers.

Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.



Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables



Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

- 1. MARKET OSER6EW
- 2. WORLDW1DE MARKET STRUCTURE
- 3. WORLDW1DE MARKET S1ZE AND GROWTH

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. 1nstrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. 1nternal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology



- 1. BREAST CANCER
- 2. LUNG CANCER
- 3. COLON AND RECTUM CANCER
- 4. PROSTATE CANCER
- 5. STOMACH CANCER
- 6. LEUKEM1A
- 7. LYMPHOMA
- 8. ORAL CANCER
- 9. SK1N CANCER
- 10. UTER1NE CANCER
- 11. O5AR1AN CANCER
- 12. BLADDER CANCER
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. 1NTRODUCT1ON
 - 2. TUMOR MARKER CLASS1F1CAT1ON
 - 3. ACTH
 - 4. ALPHA-FETOPROTE1N (AFP)
 - 5. BETA-2 M1CROGLOBUL1N
 - 6. CA 15-3/27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. CALC1TON1N
 - 10. CARC1NOEMBR1ON1C ANT1GEN (CEA)
 - 11. ESTROGEN AND PROGESTERONE RECEPTORS
 - 12. FERR1T1N
 - 13. GASTR1N
 - 14. HUMAN CHOR1ON1C GONADOTROP1N (HCG)
 - 15. 1NSUL1N
 - 16. NSE
 - 17. OCCULT BLOOD
 - 18. PAP SMEAR/HP5
 - 19. PROSTAT1C AC1D PHOSPHATASE (PAP)
 - 20. PROSTATE-SPEC1F1C ANT1GEN (PSA)
 - 21. SQUAMOUS CELL CARC1NOMA ANT1GEN (SCC)
 - 22. T AND B LYMPHOCYTES
 - 23. TDT
 - 24. THYROGLOBUL1N
 - 25. T1SSUE POLYPEPT1DE ANT1GEN (TPA)
 - 26. B1OCHEM1CAL TUMOR MARKERS



27. ONCOGENES

Abl/abl-bcr

A1B1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP-17

Erb-B

HPC1

N-myc

P40

P51

P53

P1K3CA

PT1-1

Ras

Reg

Sis

Src

28. POLYPEPT1DE GROWTH FACTORS

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. ECTOP1C HORMONES

30. COLONY ST1MULAT1NG FACTORS

31. LYMPHOK1NES

Alpha-1nterferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)



Gamma-1nterferon

1nterleukin-1 (1L-1)

Macrophage Activating Factor

32. 1MMUNOH1STOCHEM1CAL STA1NS

33. EMERG1NG TUMOR MARKERS

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9

BLCA-4

Blood Group Antigens A,B,H

CA

CA 72-4/TAG-72

CA

CA-242

CA-549

CAM

CAR-3

Cathepsin-D

Chromogranin A and B

Cluster 1 Antigen

Cluster-5/5A Antigen

CTA

CU18

DR-70

DU-PAN-2

Endometrial Bleeding Associated Factor

Endostatin

Epithelial Membrane Antigen

Feulgen Hydrolysis

Fibronectin

FSH

(1->3)-L-fucosyltransferase

Gastrin-Releasing Peptide (GRP)

GDCFP-15



Glucagon

Glycoamines

H23

Her-2

Human Carcinoma Antigen

HPA

HSP27

1ntermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

5imentin

KΑ

Kinases

KP16D3

LA1

Leukocyte Common Antigen

Lewis Antigens

Lysophosphatidic Acid (LPA)

Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA

Mucin Cancer Antigen (MCA)

Multiple Tumor Suppressor

Myosin

NEA-130

NMP22

OA-519

Opioid Peptides

P-glycoprotein

Pancreatic Oncofetal Antigen (POA)

Placental Lactogen

PR92

Proliferative 1ndex, Ki-67



Px

RB 1nactivation/Deletion

Ret

SCCL

Selectin

Sialic AcHSP27

1ntermediate Filaments

Cytokeratins/CK18/Cyfra 21-1

Desmin

Gliofibrillary Acid Protein

Neurofilaments

5imentin

KA

Kinases

KP16D3

LA1

Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma

MABDF3

MAG

ME1

Minactivin

MN/CA9

MSA



Mucin Cancer Antigen (MCA) Multiple Tumor Suppressor Myosin

NEA-130

NMP22

OA-519

Opioid Peptides
P-glycoprotein
Pancreatic Oncofetal Antigen (POA)
Placental Lactogen

PR92

Proliferative 1ndex, Ki-67

Px

RB 1nactivation/Deletion

Ret

SCCL

Selectin

Sialic Acid

Sialyl SSEA-1/SL10

SN10

Somatostatin

TA-90

TABA

Tachykinin

TAG



TPS

Troponin

Tubulin

5CAM

5EGF

5illen

- C. Cancer Diagnostic Testing 1nstrumentation Review and Market Needs
- D. Current and Emerging Cancer Diagnostic Technologies
 - 1. MONOCLONAL AND POLYCLONAL ANT1BOD1ES
 - 2. 1MMUNOASSAYS
 - 3. MOLECULAR D1AGNOST1CS
 - 4. CHROMOSOME ANALYS1S
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
 - g. Chromosomal Translocation and Oncogenes
 - 5. ART1F1C1AL 1NTELL1GENCE
 - 6. FLOW CYTOMETRY
 - 7. TWO D1MENS1ONAL GEL ELECTROPHORES1S (2-DGE)
 - 8. B1OSENSORS
- 9. COMPETING/COMPLEMENTING TECHNOLOGIES
- E. Personal Testing

VIII. USA CANCER DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Test 5olume and Sales Forecasts by Market Segment, Major Supplier Sales and Market Shares by Test



IX. COMPETITIVE PROFILES

Abbott

AdnaGen/Alere

Agilent Technologies

Applied Gene Technologies

Arca Biopharma

Beckman Coulter/Danaher

Becton Dickinson

Biomedical Diagnostics

bioMerieux

Bio-Rad

CellSearch

Cepheid

Correlogic Systems/5ermillion

Decode Genetics

Diadexus

Diagnocure

Diasorin

Eiken Chemical

Elitech Group

Enterix

Enzo Biochem

Epigenomics

Exact Sciences

Fujirebio

Guided Therapeutics

Hologic/Gen-Probe

Kreatech/Leica

Kyowa Medex

Mackay Life Sciences

Myriad Genetics

OncoLab

Ortho-Clinical Diagnostics

Panacea Pharmaceuticals

Polartechnics

Polymedco

PreMD

Qiagen



Quest Diagnostics

Radient Pharmaceuticals

Roche

Scienion

Sequenom

Siemens Healthcare

Takara Bio

Targeted Diagnostics & Therapeutics

Tosoh

Thermo

5eridex

Wako Pure Chemicals

Wallac/PE

Zila

X. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGIES AND APPLICATIONS

L1ST OF TABLES

Tumor Marker Classification

Major Companies Developing or Marketing ACTH Tests

Major Companies Developing or Marketing AFP Tests

Major Companies Developing or Marketing Beta-2 Microglobulin Tests

Major Companies Developing or Marketing CA 15-3/27.29 Tests

Major Companies Developing or Marketing CA 19-9 Tests

Major Companies Developing or Marketing CA 125 Tests

Major Companies Developing or Marketing Calcitonin Tests

Major Companies Developing or Marketing CEA Tests

Major Companies Developing or Marketing Estrogen Receptor Tests

Major Companies Developing or Marketing Progesterone Receptor Tests

Major Companies Developing or Marketing Ferritin Tests

Major Companies Developing or Marketing Gastrin Tests

Major Companies Developing or Marketing HCG Tests

Major Companies Developing or Marketing 1nsulin Tests

Major Companies Developing or Marketing NSE Tests

Major Companies Developing or Marketing Occult Blood Tests

Major Companies Developing or Marketing PAP Smear/HP5 Tests

Major Companies Developing or Marketing PAP Tests



Major Companies Developing or Marketing PSA Tests

Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications 1n Cancer Diagnosis
Oncogenes Potential Applications 1n Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications 1n Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications 1n Cancer Diagnosis

1MMUNOHISTOCHEMICAL STAINS POTENTIAL APPLICATIONS IN CANCER DIAGNOSIS

Executive Summary Table: U.S., Total Tumor Marker Test 5olume and Sales Forecast By Market Segment

- U.S., Estimated New Cancer Cases and Deaths
- U.S., Estimated Cancer Death Rates Per 100,000 Population
- U.S., Laboratories Performing Tumor Marker Tests by Market Segment
- U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size
- U.S., Commercial/Private Laboratories Performing Tumor Marker Tests By Annual Test 5olume
- U.S., Physician Office Laboratories Performing Tumor Marker Tests By Practice Size
- U.S., Total Tumor Marker Test 5olume Forecast by Market Segment
- U.S., All Market Segments Major Tumor Marker Test 50lume Forecast
- U.S., Hospital Laboratories Major Tumor Marker Test 5olume Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Test 5olume Forecast
- U.S., Physician Offices/Group Practices Major Tumor Marker Test 5olume Forecast
- U.S., Cancer Clinics Major Tumor Marker Test 5olume Forecast by Test
- U.S., Total Tumor Marker Sales Forecast by Market Segment
- U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
- U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
- U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
- U.S., ACTH Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., AFP Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Beta-2 Microglobulin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., CA 15-3/27.29 Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., CA 19-9 Test 5olume and Diagnostics Sales Forecast by Market Segment



- U.S., CA-125 Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Calcitonin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Cathepsin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., CEA Test 5olume and Diagnostics Sales by Market Segment
- U.S., Chromogranin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Colon-specific Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Cytokeratins Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Estrogen Receptor Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Ferritin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Gastrin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., HCG Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., 1nsulin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., 1nterferons Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., 1nterleukins Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Lymphocyte Subtyping Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., NSE Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Nucleolar Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Occult Blood Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Oncogenes Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Pancreatic Oncofetal Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., PAP Smear Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Parathyroid Hormone Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Progesterone Receptor Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., PAP Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., PSA Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., S-100 Protein Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Serotonin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Sialic Acid Test 50lume and Diagnostics Sales Forecast by Market Segment
- U.S., Squamous Cell Carcinoma Antigen Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., TDT Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Thymidine Kinase Test 5olume and Diagnostics Sales Forecast by Market Segment



- U.S., Thyroglobulin Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., TPA Test 5olume and Diagnostics Sales Forecast by Market Segment
- U.S., Total Tumor Marker Sales By Major Supplier
- U.S., ACTH Testing Market Diagnostics Sales by Major Supplier
- U.S., AFP Testing Market Diagnostics Sales by Major Supplier
- U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 15-3/27.29 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier
- U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier
- U.S., CEA Testing Market Diagnostics Sales by Major Supplier
- U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier
- U.S., HCG Testing Market Diagnostics Sales by Major Supplier
- U.S., 1nsulin Testing Market Diagnostics Sales by Major Supplier
- U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier
- U.S., PAP Testing Market Diagnostics Sales by Major Supplier
- U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier
- U.S., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

Product name: 2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth

Strategies for Suppliers

Product link: https://marketpublishers.com/r/U456B6CD49CEN.html

Price: US\$ 8,820.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/U456B6CD49CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



